This is a published notice on the Find a Tender service: https://www.find-tender.service.gov.uk/Notice/017321-2024

Contract

Reagents and Bioinformatics analysis

NHS Grampian

F03: Contract award notice

Notice identifier: 2024/S 000-017321

Procurement identifier (OCID): ocds-h6vhtk-046d5a

Published 4 June 2024, 4:02pm

Section I: Contracting authority

I.1) Name and addresses

NHS Grampian

Summerfield House, 2 Eday Road

Aberdeen

AB15 6RE

Email

simon.ogg@nhs.scot

Telephone

+44 3454566000

Country

United Kingdom

NUTS code

UKM50 - Aberdeen City and Aberdeenshire

Internet address(es)

Main address

http://www.nhsgrampian.org

Buyer's address

https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA00200

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Reagents and Bioinformatics analysis

Reference number

NC006-24

II.1.2) Main CPV code

• 33696500 - Laboratory reagents

II.1.3) Type of contract

Supplies

II.1.4) Short description

Next Generation Sequencing (NGS) kits

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £352,000

II.2) Description

II.2.2) Additional CPV code(s)

• 33696500 - Laboratory reagents

II.2.3) Place of performance

NUTS codes

• UKM50 - Aberdeen City and Aberdeenshire

Main site or place of performance

Aberdeen Royal Infirmary

II.2.4) Description of the procurement

Award value estimated based on previous spend for 2023-24 financial year.

This is a direct award to the existing supplier to save a significant amount of rework that would be required if the genetics lab was to switch to an alternative supplier.

This will cover the spend for 2024-25 financial year.

It is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with primary immune deficiencies and bone marrow failure and correct patient management to prevent irreversible brain damage in metabolic conditions.

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- The services can be provided only by a particular economic operator for the following reason:
 - · absence of competition for technical reasons

Explanation:

We have a number of services within the department that use Next Generation

Sequencing (NGS) kits supplied by SOPHiA Genetics. These services are funded by National Services division (NSD) and the Aberdeen laboratory provides National services for Hereditary Breast, Ovarian and prostate cancer, Cardiac arrhythmias and Whole exome sequencing (for metabolic, gastrohepatology, chromosome breakage / inherited bone marrow failure and eye disorders) using these SOPHiA kits. These are essential established reagents used in these testing pathways, having previously undergone extensive validation processes within the laboratory. Purchase of alternative reagents would involve delay to testing as additional extensive validation work would need to be undertaken before use. An integral bioinformatics solution, SOPHiA DDM, is included in the price of these SOPHiA kits which provides cost-effective, streamlined analysis for these patient samples. In addition, SOPHiA DDM is used to analyse NGS data for other rare and inherited conditions using tailored analysis pipelines. This includes Primary Immune Deficiencies, Familial Hypercholesterolaemia and tumour testing for metastatic prostate cancer. This is charged on a cost per sample upload basis and allows clinical scientists to analyse the data in an efficient manner without the need for specialist bioinformaticians. Purchase of bioinformatics services from another provider would take a significant amount of time for the validation work required to ensure accurate results are obtained and would incur significant costs for extensive validation. Furthermore, additional staff would be required to perform the bioinformatics processes that would be required in the absence of the SOPHiA DDM platform for all of the national genetics services mentioned above. It is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

Section V. Award of contract

Contract No

NC006-24

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

24 May 2024

V.2.2) Information about tenders

Number of tenders received: 1

Number of tenders received from SMEs: 0

Number of tenders received from tenderers from other EU Member States: 0

Number of tenders received from tenderers from non-EU Member States: 1

Number of tenders received by electronic means: 1

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

SOPHIA GENETICS Ltd

60 Windsor Avenue

London

SW19 2RR

Telephone

+44 7395594261

Country

United Kingdom

NUTS code

• UK - United Kingdom

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £352,000

Section VI. Complementary information

VI.3) Additional information

(SC Ref:767636)

VI.4) Procedures for review

VI.4.1) Review body

Aberdeen Sheriff Court and Justice of Peace Court

Aberdeen

Country

United Kingdom